A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome

Pharmacogenetics and Genomics

Volumn 16, Issue 5, 2006, Pages 353-357

  Martin, Annalise M ^a   Krueger, Romano ^b   Almeida, Coral Ann ^a   Nolan, David ^a   Phillips, Elizabeth ^c   Mallal, Simon ^a,b  

^a MURDOCH UNIVERSITY   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

Abacavir hypersensitivity; Flow cytometry; HLA B*5701 typing

Indexed keywords

ABACAVIR; CD45 ANTIGEN; HLA B27 ANTIGEN; MONOCLONAL ANTIBODY;

ABACAVIR HYPERSENSITIVITY SYNDROME; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSS REACTION; DRUG HYPERSENSITIVITY; FLOW CYTOMETRY; GENETIC SCREENING; HLA TYPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ALLELES; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; FLOW CYTOMETRY; GENETIC SCREENING; HISTOCOMPATIBILITY TESTING; HIV SEROPOSITIVITY; HLA-B ANTIGENS; HUMANS; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33645950777     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000197468.16126.cd     Document Type: Article

References (19)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. JAMA 1998; 279(15):1200-1205.
2. Moyle GJ, DeJesus E, Cahn P, Castillo SA, Zhao H, Gordon DN, et al. the Ziagen Once-Daily in Antiretroviral Combination Therapy (CNA30021) Study Team. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005; 38(4):417-425.
3. Chung W-H, Hung S, Hong H, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428(6982):486.
4. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134-4139.
5. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
6. Hetherington S, Hughes AR, Mostelle M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-1122.
7. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai E, et al. CNA30032 Study Team. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some but not all populations. Pharmacogenomics 2004; 5:203-211.
8. Martin A, Nolan D, Gaudieri S, Almeida C, Nolan R, James I, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004; 101(12):4180-4185.
9. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14(6):335-342.
10. Phillips EJ, Wong GA, Kaulc R, Shahabi K, Nolan DA, Knowles S, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19:979-987.
11. Terasaki PI, Bernoco F, Park MS, Ozturk G, Iwaki Y. Microdroplet testing for HLA A, B, C, and D antigens. Am J Clin Pathol 1978; 69:103-120.
12. Cereb N, Yang SY. Dimorphic primers derived from intron 1 for use in the molecular typing of HLA-B alleles. Tissue Antigens 1997; 50:74-76.
13. Sayer D, Whidborne R, Brestovac B, Trimboli F, Witt C, Christiansen F. HLA-DRB1 DNA sequencing based typing: an approach suitable for high throughput typing including unrelated bone marrow registry donors. Tissue Antigens 2001; 57:46-54.
14. Telenti A, Aubert V, Spertini F. Individualising HIV treatment - pharmacogenetics and immunogenetics. Lancet 2002; 359:722-723.
15. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003; 8(2):36-41.
16. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genom 2005; 15(5):365-369.
17. Levering WH, Wind H, Sintnicolaas K, Hooijkaas H, Gratama JW. Flow cytometric HLA-B27 screening: cross-reactivity patterns of commercially available anti-HLA-B27 monoclonal antibodies with other HLA-B antigens. Cytometry B Clin Cytom 2003; 54(1):28-38.
18. Martin AM, Nolan D, Mallal S. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens 2005; 65(6):571-574.
19. Cutrell AG, Hernandez JE, Fleming JW, Edwards MT, Moore MA, Brothers CH, Scott TR. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004; 38(12):2171-2172.